Blood test could help throat cancer patients get less radiation

NCT ID NCT05541016

First seen Sep 30, 2025 · Last updated Jun 22, 2026 · Updated 29 times

Summary

This phase II trial tests whether a blood test that detects HPV DNA can help doctors decide the right amount of radiation for people with HPV-positive throat cancer. About 455 participants will either have surgery or receive standard chemotherapy plus radiation, but the radiation dose may be lowered if the blood test shows a low risk of recurrence. The goal is to maintain high cure rates while reducing harsh side effects like trouble swallowing and dry mouth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL HUMAN PAPILLOMAVIRUS-POSITIVE SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cisplatin chemotherapy and radiation therapy, guided by a blood test (NavDx) that detects HPV DNA

What this could lead to

If successful, this approach could allow doctors to safely lower radiation doses for many patients, reducing long-term side effects without raising the risk of cancer returning.

What could go wrong

This is a mid-stage trial with 455 participants, so results are not yet proven. The blood test may not accurately predict who needs less treatment, and some patients might still experience cancer recurrence or side effects.

Conditions

The condition(s) this trial relates to.

carcinoma human papillomavirus-related squamous cell carcinoma oropharyngeal carcinoma oropharynx cancer oropharynx squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.